Investor Sentiment Improves for Haemonetics Despite Recent Lows Haemonetics shares have dropped nearly 20% this year, hitting a 52-week low. However, short interest has recently declined, and institutional ownership remains high. Analysts expect earnings growth of over 10% next year, with the average price target suggesting significant upside, signaling renewed confidence in the company’s recovery potential.65